Biotech Company Auxilium Explodes After Takeover Offer
The offer values Auxilium at $28.10 per share and is comprised of an equal mix of cash and Endo stock.
Endo's offer represents a 31% premium to Auxilium's closing price on Tuesday, and a 40% premium to the closing price of Auxilium over the last 30 days. In after hours trade on Tuesday Auxilium shares were trading as high as $30.70.
Following the announcement, Endo shares were also higher, up more than 4%.
The offer also follows an announcement from Auxilium last week that the company would cut 30% of its staff as part of cost-saving measures aimed as saving $75 million per year.
Auxilium's portfolio of drugs includes: edex®, an injectable treatment for erectile dysfunction, Osbon® ErecAid®, a device for aiding erectile dysfunction, STENDRA®, an oral erectile dysfunction therapy, TESTOPEL®, a long-acting implantable testosterone replacement therapy, XIAFLEX®, for the treatment of Peyronie's disease and XIAFLEX for the treatment of Dupuytren's contracture, among other drugs.
- Love in the time of elections: Do politics spice up or spoil dating in India?
- Samsung Galaxy S24 Plus review – the best smartphone in the S24 lineup
- Household savings dip over Rs 9 lakh cr in 3 years to Rs 14.16 lakh cr in 2022-23
- Misleading ads: SC says public figures must act with responsibility while endorsing products
- Here’s what falling inside a black hole would look like, according to a NASA supercomputer simulation